Nevertheless, these findings point to complex interaction between GLP-1 and the gut, brain, immune system, and gut microbiota in control of inflammation (Figure 3 and Figure 4), offering osteoarthritis as a relevant inflammation model to explore the systemic, integrative actions of GLP-1 medicines beyond metabolic control (Figure 4). The gene discussed is GCG; the disease is osteoarthritis.